GlaxoSmithKline says net profits drop 13% in Q1

British drugsmaker GlaxoSmithKline said Wednesday that its net profits dropped 13 percent to £1.325 billion (1.616 billion euros, $2.134 billion) in the first quarter from a year earlier.

The result was skewed by the fact GSK had its earnings after tax boosted in the first quarter of 2011 by the sale of its stake in medical testing business Quest Diagnostics.

GSK added in a statement that group revenue rose 1.0 percent to £6.64 billion in the first three months of 2012 compared with the first quarter in 2011.

"This (first) quarter (in 2012) marked continued progress for the group as we returned to reported sales growth," GSK chief executive Andrew Witty said in the company's results statement.

"We remain mindful of the challenges we face given the current global political and economic environment, particularly in relation to pricing on our more established products.

"However, we also continue to see attractive growth opportunities across our businesses and we intend to continue to invest behind them to strengthen the breadth and mix of the group and its future growth prospects," he added.

GSK added that it was raising its 2012 share buyback target to £2.0 billion-£2.5 billion after agreeing in the first quarter to sell a stable of over-the-counter brands to Belgium's Omega Pharma.

Also in the first quarter, GSK said it would create 1,000 jobs and open a new production site in northern England.

Earlier this month meanwhile, the drugs giant bid $2.6 billion for US research partner Human Genome Sciences Inc.

add to favorites email to friend print save as pdf

Related Stories

GlaxoSmithKline posts rising Q3 profits

Oct 26, 2011

British drugmaker GlaxoSmithKline said Wednesday that third-quarter net profit rose seven percent, boosted by growth across its main pharmaceuticals, vaccines and consumer healthcare divisions.

GSK to take $3.4 bln Avandia legal charge

Jan 17, 2011

British drugs firm GlaxoSmithKline said Monday it expects to take a legal charge of £2.2 billion linked to its former blockbuster diabetes product Avandia, sparking a sharp drop in its shares.

Recommended for you

Vaccine proves effective against deadly Middle East virus

15 hours ago

(Medical Xpress)—A vaccine developed by an international team of scientists led by the University of Pittsburgh School of Medicine successfully protects mice against a contagious and deadly virus spreading across the Middle ...

New study looks at improving vaccine awareness

16 hours ago

The best medical therapies won't do much good if the public abstains from using them. Resistance to life-saving interventions may have a variety of root causes, particularly if the biotechnology involved is new and poorly ...

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

User comments